UNIVAX

"A “Universal” Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines"

Coordinatore	EIDGENOESSISCHES DEPARTEMENT DES INNERN    more  Organization address address: Inselgasse 1 city: BERN postcode: 3003 contact info Titolo: Mrs. Nome: Caroline Cognome: De St. Simon Email: send email Telefono: +41 318489231 Fax: +41 31 848 9222
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	7˙803˙864 €
EC contributo	5˙999˙457 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2018-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	EIDGENOESSISCHES DEPARTEMENT DES INNERN  Organization address address: Inselgasse 1 city: BERN postcode: 3003 contact info Titolo: Mrs. Nome: Caroline Cognome: De St. Simon Email: send email Telefono: +41 318489231 Fax: +41 31 848 9222	CH (BERN)	coordinator	1˙181˙117.00
2	UNIVERSITETET I BERGEN  Organization address address: Museplassen 1 city: BERGEN postcode: 5007 contact info Titolo: Ms. Nome: Liv-Grethe Cognome: Gudmundsen Email: send email Telefono: 4755584965 Fax: 4755584991	NO (BERGEN)	participant	735˙771.00
3	THE UNIVERSITY OF MANCHESTER  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Claire Cognome: Faichnie Email: send email Telefono: +44 1612751413	UK (MANCHESTER)	participant	683˙534.00
4	HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH  Organization address address: Inhoffenstrasse 7 city: BRAUNSCHWEIG postcode: 38124 contact info Titolo: Dr. Nome: Michael Cognome: Strätz Email: send email Telefono: +49 53161812020 Fax: +49 53161812299	DE (BRAUNSCHWEIG)	participant	618˙628.00
5	OZ BIOSCIENCES SAS  Organization address address: Parc scientifique et Technologique de Luminy - BAT CCIMP city: MARSEILLE postcode: 13288 contact info Titolo: Dr. Nome: Olivier Cognome: Zelphati Email: send email Telefono: +33 486948514 Fax: +33 486948515	FR (MARSEILLE)	participant	535˙900.00
6	AMVAC RESEARCH GMBH  Organization address address: LOCHHAMER STRASSE 29 A city: MARTINSRIED postcode: 82152 contact info Titolo: Dr. Nome: Marian Cognome: Wiegand Email: send email Telefono: +49 8963854363	DE (MARTINSRIED)	participant	468˙640.00
7	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE  Organization address address: Rue Michel -Ange 3 city: PARIS postcode: 75794 contact info Titolo: Dr. Nome: Camille Cognome: Sèze-Goismier Email: send email Telefono: +33 238255010	FR (PARIS)	participant	467˙430.00
8	VITAMFERO SA  Organization address address: RUE PIERRE FONTAINE 4 city: EVRY postcode: 91058 contact info Titolo: Dr. Nome: Edouard Cognome: Sèche Email: send email Telefono: +33 619654523 Fax: +33 247367050	FR (EVRY)	participant	439˙800.00
9	MEDITOX S.R.O  Organization address address: POD ZAMKEM 279 city: KONAROVICE postcode: 28125 contact info Titolo: Dr. Nome: Martin Cognome: Slais Email: send email Telefono: +420 313129375 Fax: +420 313129366	CZ (KONAROVICE)	participant	413˙277.00
10	TP21 GMBH  Organization address address: LUISENSTRASSE 14 city: BERLIN postcode: 10117 contact info Titolo: Dr. Nome: Petra Cognome: Zalud Email: send email Telefono: +49 6813906719 Fax: +41 313114790	DE (BERLIN)	participant	268˙000.00
11	SYNTHAUR OOO  Organization address address: UL MIKLUKHO MAKLAYA 16/10 city: MOSKVA postcode: 117997 contact info Titolo: Prof. Nome: Nicolai Cognome: Bovin Email: send email Telefono: +7 4953307138 Fax: +7 4953305592	RU (MOSKVA)	participant	187˙360.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Although vaccination is the cornerstone of prophylaxis, current vaccines provide only moderate protection. Most employ inactivated or protein-based, including multimeric antigen, vaccines requiring annual updating. Their limited antigen loads provide limited capacity for inducing robust immune defences, without assurance that both humoral and cell mediated (CMI) responses, as well as durable immunity, will be induced. Replicating vaccines may provide several rounds of antigen production, increasing potential for humoral and CMI defence induction. Neither live, attenuated nor vector vaccines can be produced synthetically, being reliant on cell culture or egg production. They cannot be targeted to immune cells; interference from pre-existing immunity is also a risk. Efficacious, synthetic vaccines would be the answer, as seen with self-replicating RNA replicon (RepRNA) technology – these replicate and translate without producing infectious progeny. RepRNA produced in vitro is combined with synthetic delivery vehicles targeting dendritic cell (DC) receptors –essential for efficient immune defences– with glycoconjugate ligands. The UniVax project promotes the first synergising of approaches with synthetic targeted delivery systems for RepRNA. The innovation integrates technologies of (i) RepRNA vaccines, (ii) lipoplexes (biodegradable lipid/adjuvant/RNA for cytosolic delivery), (iii) polyplexes (biodegradable, polysaccharide vehicles), (iv) glycoconjugates targeting DC receptors, (v) adjuvants with well-defined molecular targets and effector functions. This promotes efficacious mucosal and systemic responses, ensuring for the first time both humoral and CMI responses. Components developed in PANFLUVAC and Replixcel projects allow UniVax to create the first Universal” Flu vaccine prototypes. This innovative approach creates the first synthetic vaccine of its kind, promoting consortium SMEs to a unique position of world leaders.'